- Home
- LEGN vs NUVL Comparison
LEGN vs NUVL Comparison
Compare LEGN & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGN
- NUVL
- Stock Information
- Founded
- LEGN 2014
- NUVL 2017
- Country
- LEGN United States
- NUVL United States
- Employees
- LEGN N/A
- NUVL N/A
- Industry
- LEGN Biotechnology: Pharmaceutical Preparations
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- LEGN Health Care
- NUVL Health Care
- Exchange
- LEGN Nasdaq
- NUVL Nasdaq
- Market Cap
- LEGN 6.0B
- NUVL 6.7B
- IPO Year
- LEGN 2020
- NUVL 2021
- Fundamental
- Price
- LEGN $32.66
- NUVL $75.84
- Analyst Decision
- LEGN Strong Buy
- NUVL Strong Buy
- Analyst Count
- LEGN 13
- NUVL 11
- Target Price
- LEGN $80.62
- NUVL $112.36
- AVG Volume (30 Days)
- LEGN 1.3M
- NUVL 558.9K
- Earning Date
- LEGN 03-10-2025
- NUVL 02-25-2025
- Dividend Yield
- LEGN N/A
- NUVL N/A
- EPS Growth
- LEGN N/A
- NUVL N/A
- EPS
- LEGN N/A
- NUVL N/A
- Revenue
- LEGN $520,183,000.00
- NUVL N/A
- Revenue This Year
- LEGN $120.36
- NUVL N/A
- Revenue Next Year
- LEGN $67.91
- NUVL N/A
- P/E Ratio
- LEGN N/A
- NUVL N/A
- Revenue Growth
- LEGN 122.96
- NUVL N/A
- 52 Week Low
- LEGN $30.17
- NUVL $61.80
- 52 Week High
- LEGN $70.13
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- LEGN 41.28
- NUVL 38.09
- Support Level
- LEGN $30.17
- NUVL $69.58
- Resistance Level
- LEGN $37.92
- NUVL $78.18
- Average True Range (ATR)
- LEGN 2.07
- NUVL 3.03
- MACD
- LEGN 0.12
- NUVL 0.04
- Stochastic Oscillator
- LEGN 32.13
- NUVL 50.40
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.